Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern.
Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern.
复制标题
DOI：
10.3168/jds.2021-21247
复制
发表时间：
2022-04
影响因子：
3.5
通讯作者：
Sexton JZ
中科院分区：
文献类型：
--
作者：
Wotring JW;Fursmidt R;Ward L;Sexton JZ
Bovine lactoferrin (bLF), a naturally occurring glycoprotein found in milk, has bioactive characteristics against many microbes, viruses, and other pathogens. Bovine lactoferrin strongly inhibits SARS-CoV-2 infection in vitro through direct entry inhibition and immunomodulatory mechanisms. This study reports on the anti-SARS-CoV-2 efficacy of commercially available bLF and common dairy ingredients in the human lung cell line H1437 using a custom high-content imaging and analysis pipeline. We also show for the first time that bLF has potent efficacy across different viral strains including the South African B.1.351, UK B.1.1.7, Brazilian P.1, and Indian Delta variants. Interestingly, we show that bLF is most potent against the B.1.1.7 variant [half-maximal inhibitory concentration (IC50) = 3.7 µg/mL], suggesting that this strain relies on entry mechanisms that are strongly inhibited by bLF. We also show that one of the major proteolysis products of bLF, lactoferricin B 17–41, has a modest anti-SARS-CoV-2 activity that could add to the clinical significance of this protein for SARS-CoV-2 treatment as lactoferricin is released by pepsin during digestion. Finally, we show that custom chewable lactoferrin tablets formulated in dextrose or sorbitol have equivalent potency to unformulated samples and provide an option for future human clinical trials. Lactoferrin's broad inhibition of SARS-CoV-2 variants in conjunction with the low cost and ease of production make this an exciting clinical candidate for treatment or prevention of SARS-CoV-2 in the future.
登录
查看更多内容
影响因子：
9.8
作者：
McQuin C;Goodman A;Chernyshev V;Kamentsky L;Cimini BA;Karhohs KW;Doan M;Ding L;Rafelski SM;Thirstrup D;Wiegraebe W;Singh S;Becker T;Caicedo JC;Carpenter AE
通讯作者：
Carpenter AE
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
5.6
作者：
Rosa L;Cutone A;Lepanto MS;Paesano R;Valenti P
通讯作者：
Valenti P
影响因子：
2
作者：
Redwan, Elrashdy M.;Uversky, Vladimir N.;Al-Mehdar, Hussein
通讯作者：
Al-Mehdar, Hussein
DOI：
10.1073/pnas.2105815118
发表时间：
2021-09-07
影响因子：
11.1
作者：
Mirabelli C;Wotring JW;Zhang CJ;McCarty SM;Fursmidt R;Pretto CD;Qiao Y;Zhang Y;Frum T;Kadambi NS;Amin AT;O'Meara TR;Spence JR;Huang J;Alysandratos KD;Kotton DN;Handelman SK;Wobus CE;Weatherwax KJ;Mashour GA;O'Meara MJ;Chinnaiyan AM;Sexton JZ
通讯作者：
Sexton JZ